The independent source for health policy research, polling, and news.
221 - 240 of 1,305 Results
Monica Bertagnolli, the president鈥檚 choice to head the National Institutes of Health, appeared before a Senate committee this week. Her confirmation has been held up by Sen. Bernie Sanders (I-Vt.), who has demanded President Joe Biden work more aggressively to lower prescription drug prices.
Open enrollment for Medicare beneficiaries with private health plans began Oct. 15, to be followed Nov. 1 by open enrollment for Affordable Care Act plans. The selection for both is large 鈥 often too large to be navigated easily alone. And people who choose incorrectly can end up with unaffordable medical bills. Meanwhile, those on both sides of the abortion issue are looking to Ohio鈥檚 November ballot measure on abortion to see whether anti-abortion forces can break their losing streak in statewide ballot questions since the overturn of Roe v. Wade in 2022.
A bitterly divided Congress managed to keep the federal government running for several more weeks, while House Republicans struggle 鈥 again 鈥 to choose a leader. Meanwhile, many people removed from state Medicaid rolls are not finding their way to Affordable Care Act insurance, and a major investigation by The Washington Post attributes the decline in U.S. life expectancy to more than covid-19 and opioids. Lauren Weber of The Washington Post, Victoria Knight of Axios, and Sarah Karlin-Smith of the Pink Sheet join 51视频 Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews physician-author-playwright Samuel Shem about 鈥淥ur Hospital,鈥 his new novel about the health workforce in the age of covid.
Pharmaceutical patents can drive up the costs of lifesaving medications. Hear what author and YouTube star John Green is doing to make tuberculosis drugs more accessible to the people who need them most.
Former President Donald Trump, who鈥檚 running for another term in the White House, recently blamed drug shortages on his successor, President Joe Biden. Our findings don鈥檛 align with Trump鈥檚 claims; by some measures, drug shortages increased more on Trump鈥檚 watch than on Biden鈥檚.
A report by the U.S. Department of Health and Human Services raises troubling questions about the use of powerful medications within Florida鈥檚 child welfare system and the risk of overdoses or dangerous side effects if children are given the wrong combination of drugs.
Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join 51视频 Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for 鈥渆xtra credit,鈥 the panelists suggest health policy stories they read this week they think you should read, too.
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it鈥檚 time for new boosters 鈥 and not only for those at highest risk of serious disease. Here are seven things you need to know.
51视频 Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.
A Colorado board has named five drugs it will review for affordability and potential cost caps. But patients with cystic fibrosis worry they will lose access to a life-changing therapy.
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
To contain the opioid crisis, health and law enforcement agencies have turned to technology to monitor doctor and patient prescription data. Experts have raised questions about how these systems work and worry about their accuracy and potential biases. Some patients and doctors say they鈥檙e being unfairly targeted.
Brand-name drug prices in the U.S. 鈥 more than three times the price in other developed countries 鈥 are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
A federal appeals court issued a split decision on whether the abortion pill mifepristone should remain on the market 鈥 rejecting a lower court鈥檚 decision to effectively cancel the drug鈥檚 FDA approval in 2000, while ordering the rollback of more recent rules that made the drug easier to obtain. Nothing changes immediately, however, as the Supreme Court blocked the lower court鈥檚 ruling in the spring. It will be up to the high court to determine whether the pill remains available in the U.S. and under which conditions. Sarah Karlin-Smith of the Pink Sheet, Alice Miranda Ollstein of Politico, and Shefali Luthra of The 19th join 51视频 Health News鈥 chief Washington correspondent, Julie Rovner, to discuss these issues and more. Plus, for 鈥渆xtra credit,鈥 the panelists suggest health policy stories they read this week they think you should read, too.
51视频 Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
PBS NewsHour featured 51视频 Health News鈥 Aneri Pattani as it reported on how this debate is playing out in North Carolina and Ohio.
Clinics serving Alzheimer鈥檚 patients are working out the details of who will get treated with the new drug Leqembi. It won鈥檛 be for everyone with memory-loss symptoms.
Nearly a year to the day after Kansas voters surprised the nation by defeating an anti-abortion ballot question, Ohio voters defeated a similar, if cagier, effort to limit access in that state. This week, they rejected an effort to raise the threshold for approval of future ballot measures from a simple majority, which would have made it harder to protect abortion access with yet another ballot question come November. Meanwhile, the number of Americans without health insurance has dropped to an all-time low, though few noticed. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Roubein of The Washington Post, and Emmarie Huetteman of 51视频 Health News join 51视频 Health News鈥 chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Kate McEvoy, executive director of the National Association of Medicaid Directors, about how the 鈥淢edicaid unwinding鈥 is going, as millions have their eligibility for coverage rechecked.
漏 2026 51视频